Andreas Wollenberg

73PUBLICATIONS
174CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Disease surveillanceMajor global burdens of diseaseAllergyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (73)

|May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

|Feb 05, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh

|Jan 31, 2026
Severity bands for atopic dermatitis measures: Analysis from adult dupilumab randomized clinical trials.

Andreas Wollenberg, Eric L Simpson, Yael A Leshem

|Nov 15, 2025
Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema.

David Cohen, Anthony Bewley, Andreas Wollenberg

|Nov 09, 2025
Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis.

Jonathan I Silverberg, Andreas Wollenberg, Linda Stein Gold

|Oct 16, 2025
Cost-Per-Responder Analysis for Tralokinumab and Dupilumab in Combination with Topical Corticosteroids in Patients with Moderate-To-Severe Atopic Dermatitis.

Marni Wiseman, Marco Benvenuto, Liv Strømkjær

Pageof 13

Frequent Collaborators

12 joint publications

Jonathan I Silverberg

10 joint publications

Carsten Flohr

9 joint publications

Matthias Augustin

8 joint publications

Annice Heratizadeh